Immunic, Inc.
HealthcareNASDAQ:IMUX · NASDAQ Global Select
+$0.79 today
Vol 0.20M · Avg 0.28M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
1456.2%
avg -22.8%
ROIC
1693.4%
avg 1.5%
ROA
-404.0%
avg -140.7%
Analysis
ROIC is currently the strongest return metric at 1693.4% versus its period average of 1.5%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel Vitt | Chief Executive Officer & Director | $1.13M | — | 58 | $1.72M | 17.43% |
Michael A. Panzara | Chief Medical Officer | $809,825.00 | — | 59 | $0.00 | <0.01% |
Andreas Muehler | Chief Medical Officer | $809,825.00 | — | 61 | $660,000.00 | 6.69% |
Jason Tardio | Chief Operating Officer & President | $751,700.00 | — | 49 | $660,000.00 | 6.69% |
Glenn Whaley | Chief Financial Officer | $682,250.00 | — | 58 | $560,000.00 | 5.67% |
Erik Lundgren | Chief Executive Officer | — | — | 48 | $0.00 | <0.01% |
Patrick Walsh | Chief Business Officer | — | — | 43 | — | — |
Hella Kohlhof | Chief Scientific Officer | — | — | 53 | — | — |
Inderpal Singh | General Counsel | — | — | 60 | — | — |
Werner Gladdines | Chief Development Officer | — | — | 47 | — | — |
Jessica Breu | Vice President of Investor Relations & Communications | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$16,694.00
Sells
0
$0.00
Net Sentiment
+$16,694.00
Net buying
Most Active
Nash Duane
1 transactions
Analysis
Insiders reported 1 buys worth $16,694.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $16,694.00. Nash Duane was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Vaxart, Inc.
NASDAQ:VXRT
$136.13M
Repare Therapeutics Inc.
RPTX
$114.24M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
PMV Pharmaceuticals, Inc.
NASDAQ:PMVP
$59.20M
Cibus, Inc.
NASDAQ:CBUS
$55.95M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Lite Strategy, Inc.
LITS
$25.22M
Who manages IMUX?
Immunic, Inc. (IMUX) lists 11 active executives. The top listed executive is Daniel Vitt, Chief Executive Officer & Director.
Are IMUX insiders buying or selling?
Recent insider activity shows net buying of $32.80M.
Explore More
Continue the stock analysis
Jump to another research area for this company.